See more : Broncus Holding Corporation (2216.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Qianhai Health Holdings Limited (0911.HK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Qianhai Health Holdings Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Hormel Foods Corporation (HO7.DE) Income Statement Analysis – Financial Results
- Vamshi Rubber Limited (VAMSHIRU.BO) Income Statement Analysis – Financial Results
- UBTECH Robotics Corp Ltd (9880.HK) Income Statement Analysis – Financial Results
- Almaden Minerals Ltd. (AMM.TO) Income Statement Analysis – Financial Results
- Immuron Limited (IMRN) Income Statement Analysis – Financial Results
Qianhai Health Holdings Limited (0911.HK)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.qianhaihealth.com.hk
About Qianhai Health Holdings Limited
Qianhai Health Holdings Limited, an investment holding company, engages in the sale of health products and electronic component products in Hong Kong. The company operates through Health-Care Products and Electronic Component Products segments. It offers Chinese herbal medicines, and skincare and other health-care products to wholesalers and retailers, as well as American ginseng, a perennial plant. The company is also involved in the sale of electronic components, including central processing unit, semi-conductor, etc. In addition, it engages in the trading of health-care products and electronic components; and money lending business. The company was formerly known as Hang Fat Ginseng Holdings Company Limited and changed its name to Qianhai Health Holdings Limited in September 2016. The company was founded in 1989 and is based in Sheung Wan, Hong Kong. Qianhai Health Holdings Limited is a subsidiary of Explorer Rosy Limited.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 961.29M | 1.96B | 283.40M | 760.72M | 587.81M | 78.05M | 197.06M | 354.39M | 835.53M | 1.22B | 762.97M | 492.28M |
| Cost of Revenue | 996.89M | 1.89B | 267.36M | 715.59M | 555.13M | 75.04M | 188.14M | 752.28M | 822.30M | 917.19M | 583.55M | 411.88M |
| Gross Profit | -35.60M | 76.48M | 16.04M | 45.13M | 32.68M | 3.00M | 8.92M | -397.90M | 13.24M | 302.46M | 179.42M | 80.40M |
| Gross Profit Ratio | -3.70% | 3.90% | 5.66% | 5.93% | 5.56% | 3.85% | 4.53% | -112.28% | 1.58% | 24.80% | 23.52% | 16.33% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 16.61M | 19.19M | 20.52M | 23.88M | 21.14M | 30.96M | 33.32M | 60.27M | 156.92M | 55.08M | 20.85M | 1.73M |
| Selling & Marketing | 142.00K | 166.00K | 158.00K | 1.44M | 933.00K | 3.68M | 1.64M | 4.24M | 31.64M | 6.96M | 3.64M | 1.70M |
| SG&A | 16.75M | 19.36M | 20.67M | 25.31M | 22.07M | 34.64M | 34.96M | 64.51M | 188.57M | 62.04M | 24.48M | 16.54M |
| Other Expenses | 351.00K | 313.92M | -11.42M | 13.19M | -178.00K | 666.00K | 2.65M | -14.19M | 2.62M | 1.92M | 1.92M | 0.00 |
| Operating Expenses | 17.10M | 333.27M | 20.67M | 38.51M | 21.90M | 34.62M | 34.59M | 64.33M | 188.57M | 61.98M | 24.48M | 4.01M |
| Cost & Expenses | 1.01B | 2.22B | 288.03M | 754.10M | 577.02M | 109.66M | 222.73M | 816.61M | 1.01B | 979.17M | 608.03M | 415.89M |
| Interest Income | 69.00K | 100.00K | 119.00K | 141.00K | 17.78M | 22.59M | 15.43M | 8.33M | 49.72M | 6.79M | 6.00K | 15.62M |
| Interest Expense | 43.00K | 34.00K | 508.00K | 1.77M | 1.44M | 233.00K | 76.00K | 21.44M | 42.20M | 12.02M | 11.00M | 0.00 |
| Depreciation & Amortization | 2.43M | 2.43M | 2.44M | 3.02M | 2.41M | 1.87M | 3.17M | 4.94M | 4.47M | 2.54M | 2.00M | 2.58M |
| EBITDA | -50.23M | -231.24M | 2.06M | 5.63M | 31.95M | -11.73M | -19.85M | -529.66M | -350.19M | 260.89M | 165.94M | 79.12M |
| EBITDA Ratio | -5.23% | -12.91% | -0.29% | 1.03% | 5.50% | 7.28% | 8.74% | -153.12% | -22.46% | 20.10% | 21.72% | 12.97% |
| Operating Income | -52.71M | -256.79M | -4.64M | 4.80M | 28.10M | -13.83M | 29.79M | -450.94M | -352.55M | 241.36M | 163.94M | 61.27M |
| Operating Income Ratio | -5.48% | -13.09% | -1.64% | 0.63% | 4.78% | -17.72% | 15.12% | -127.24% | -42.19% | 19.79% | 21.49% | 12.45% |
| Total Other Income/Expenses | 0.00 | 0.00 | 3.75M | -1.64M | -1.39M | 8.82M | 6.13M | 0.00 | -89.96M | -27.61M | -2.87M | -503.00K |
| Income Before Tax | -52.71M | -233.70M | -888.00K | -804.00K | 26.72M | -5.02M | 35.92M | -564.49M | -396.86M | 230.74M | 152.94M | 60.77M |
| Income Before Tax Ratio | -5.48% | -11.91% | -0.31% | -0.11% | 4.54% | -6.43% | 18.23% | -159.29% | -47.50% | 18.92% | 20.05% | 12.34% |
| Income Tax Expense | 0.00 | -21.95M | -2.37M | 5.60M | 3.19M | -10.05M | 59.00K | -38.63M | 41.66M | 25.42M | 24.33M | 28.43M |
| Net Income | -52.71M | -211.75M | 1.48M | -6.41M | 26.72M | 5.07M | 35.86M | -525.71M | -438.40M | 205.35M | 128.61M | 32.34M |
| Net Income Ratio | -5.48% | -10.79% | 0.52% | -0.84% | 4.54% | 6.50% | 18.20% | -148.34% | -52.47% | 16.84% | 16.86% | 6.57% |
| EPS | -0.03 | -1.25 | 0.01 | -0.04 | 0.16 | 0.03 | 0.02 | -3.73 | -6.57 | 0.47 | 0.34 | 0.65 |
| EPS Diluted | -0.03 | -1.25 | 0.01 | -0.04 | 0.16 | 0.03 | 0.21 | -3.73 | -6.57 | 0.47 | 0.34 | 0.65 |
| Weighted Avg Shares Out | 1.69B | 169.45M | 169.30M | 169.28M | 169.28M | 169.39M | 170.04M | 140.95M | 66.71M | 43.94M | 50.00M | 50.00M |
| Weighted Avg Shares Out (Dil) | 1.69B | 169.45M | 169.30M | 169.28M | 169.28M | 169.39M | 170.04M | 140.95M | 66.71M | 43.94M | 50.00M | 50.00M |
Source: https://incomestatements.info
Category: Stock Reports